Liposomal amphotericin B as a treatment for human leishmaniasis

Hdl Handle:
http://hdl.handle.net/10144/255342
Title:
Liposomal amphotericin B as a treatment for human leishmaniasis
Authors:
Balasegaram, Manica; Ritmeijer, Koert; Lima, Maria Angeles; Burza, Sakib; Ortiz Genovese, Gemma; Milani, Barbara; Gaspani, Sara; Potet, Julien; Chappuis, François
Journal:
Expert Opinion on Emerging Drugs
Affiliation:
Drugs for Neglected Diseases Initiative, Geneva, Switzerland;2 Médecins Sans Frontières, Operational Centre Amsterdam, Amsterdam, The Netherlands; Médecins Sans Frontières, Operational Centre Barcelona Athens, Barcelona, Spain; Médecins Sans Frontières, Access Campaign, Paris, France; Médecins Sans Frontières, Operational Centre Geneva, Geneva, Switzerland;Médecins Sans Frontières, Access Campaign, Geneva, Switzerland; University of Geneva, andGeneva University Hospitals, Division of International and Humanitarian Medicine, 6, rue Gabrielle-Perret-Gentil, 1211 Geneva 14, Switzerland.
Publisher:
Informa
Issue Date:
11-Dec-2012
URI:
http://hdl.handle.net/10144/255342
DOI:
10.1517/14728214.2012.748036
Additional Links:
http://informahealthcare.com/doi/abs/10.1517/14728214.2012.748036
Submitted date:
2012-11
Type:
Article
Language:
en
ISSN:
1472-8214; 1744-7623
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorBalasegaram, Manicaen_GB
dc.contributor.authorRitmeijer, Koerten_GB
dc.contributor.authorLima, Maria Angelesen_GB
dc.contributor.authorBurza, Sakiben_GB
dc.contributor.authorOrtiz Genovese, Gemmaen_GB
dc.contributor.authorMilani, Barbaraen_GB
dc.contributor.authorGaspani, Saraen_GB
dc.contributor.authorPotet, Julienen_GB
dc.contributor.authorChappuis, Françoisen_GB
dc.date.accessioned2012-12-11T20:36:10Z-
dc.date.available2012-12-11T20:36:10Z-
dc.date.issued2012-12-11-
dc.date.submitted2012-11-
dc.identifier.citationLiposomal amphotericin B as a treatment for human leishmaniasis 2012, 17 (4):493 Expert Opinion on Emerging Drugsen_GB
dc.identifier.issn1472-8214-
dc.identifier.issn1744-7623-
dc.identifier.doi10.1517/14728214.2012.748036-
dc.identifier.urihttp://hdl.handle.net/10144/255342-
dc.language.isoenen
dc.publisherInformaen_GB
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.1517/14728214.2012.748036en_GB
dc.rightsArchived with thanks to Expert Opinion on Emerging Drugsen_GB
dc.subjectLeishmaniasisen_GB
dc.titleLiposomal amphotericin B as a treatment for human leishmaniasisen
dc.typeArticleen
dc.contributor.departmentDrugs for Neglected Diseases Initiative, Geneva, Switzerland;2 Médecins Sans Frontières, Operational Centre Amsterdam, Amsterdam, The Netherlands; Médecins Sans Frontières, Operational Centre Barcelona Athens, Barcelona, Spain; Médecins Sans Frontières, Access Campaign, Paris, France; Médecins Sans Frontières, Operational Centre Geneva, Geneva, Switzerland;Médecins Sans Frontières, Access Campaign, Geneva, Switzerland; University of Geneva, andGeneva University Hospitals, Division of International and Humanitarian Medicine, 6, rue Gabrielle-Perret-Gentil, 1211 Geneva 14, Switzerland.en_GB
dc.identifier.journalExpert Opinion on Emerging Drugsen_GB
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.